Meters & Strips($9B)
Lancets($1.3B)
Syringe($0.8B)
InsulinInhaler
Oral Anti-Diabetics(S-U, TZD,Met)
($30B)
GLP-1($1.7B)
Insulin($15B)
Patient CGM
($0.25B)
InsulinPumps
($0.75B)
Pro CGM
($0.02B)
POC A1C/ AG1,5
($0.3B)
DPP-4($6.8B)
Non-InvasiveGlucose
Meter
Scholz Consulting Partners LLC ° Diabetes Practice
• Continuous Glucose Monitoring • Non-invasive Glucose Monitoring• Glycemic Control in the ICU• Emerging therapies in T1DM• Oral, transdermal, and inhaled insulin• mHealth and remote monitoring
Bryce [email protected]
Manfred Scholz, PhD, [email protected]
Therapies Delivery DiagnosticsPens
($0.52B)
Selected Diabetes Markets and Companies
Oral/ Inhaled/Trans-dermal Insulin
ICU CGM
($0.15B)
Oral GLP-1
Ketone,µAlb
($0.2B)
Recommended
